Shares of Intersect ENT Inc (NASDAQ:XENT) have earned an average rating of “Buy” from the ten research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $41.25.

A number of equities analysts recently commented on XENT shares. BidaskClub cut Intersect ENT from a “buy” rating to a “hold” rating in a report on Tuesday, July 17th. ValuEngine cut Intersect ENT from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 16th. BTIG Research restated a “hold” rating on shares of Intersect ENT in a report on Thursday, August 2nd. Canaccord Genuity restated a “buy” rating on shares of Intersect ENT in a report on Wednesday, August 1st. Finally, Piper Jaffray Companies lowered their target price on Intersect ENT from $45.00 to $40.00 and set an “overweight” rating for the company in a report on Wednesday, August 1st.

In related news, Director Dana G. Jr. Mead acquired 3,811 shares of the firm’s stock in a transaction dated Monday, August 6th. The stock was acquired at an average price of $26.22 per share, for a total transaction of $99,924.42. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Lisa D. Earnhardt sold 20,000 shares of Intersect ENT stock in a transaction dated Monday, July 16th. The shares were sold at an average price of $33.08, for a total value of $661,600.00. Following the completion of the transaction, the chief executive officer now owns 474,683 shares of the company’s stock, valued at approximately $15,702,513.64. The disclosure for this sale can be found here. Insiders sold a total of 79,833 shares of company stock valued at $2,390,870 in the last quarter. Company insiders own 5.90% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new position in shares of Intersect ENT in the 1st quarter valued at about $132,000. Meeder Asset Management Inc. raised its position in shares of Intersect ENT by 565.6% during the 2nd quarter. Meeder Asset Management Inc. now owns 3,987 shares of the medical equipment provider’s stock worth $149,000 after acquiring an additional 3,388 shares in the last quarter. UBS Group AG raised its position in shares of Intersect ENT by 81.1% during the 1st quarter. UBS Group AG now owns 4,679 shares of the medical equipment provider’s stock worth $184,000 after acquiring an additional 2,096 shares in the last quarter. Aperio Group LLC acquired a new stake in shares of Intersect ENT during the 1st quarter worth about $213,000. Finally, All Terrain Financial Advisors LLC acquired a new stake in shares of Intersect ENT during the 1st quarter worth about $241,000. Institutional investors and hedge funds own 90.30% of the company’s stock.

Shares of NASDAQ XENT traded up $0.05 during mid-day trading on Friday, reaching $28.45. 164,100 shares of the company’s stock were exchanged, compared to its average volume of 305,897. The stock has a market cap of $884.70 million, a PE ratio of -50.89 and a beta of 0.56. Intersect ENT has a 52-week low of $25.15 and a 52-week high of $42.95.

Intersect ENT (NASDAQ:XENT) last released its quarterly earnings results on Wednesday, August 1st. The medical equipment provider reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. The business had revenue of $26.30 million during the quarter, compared to analysts’ expectations of $28.15 million. Intersect ENT had a negative return on equity of 15.01% and a negative net margin of 17.22%. The company’s revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.08) EPS. analysts expect that Intersect ENT will post -0.86 EPS for the current fiscal year.

Intersect ENT Company Profile

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Featured Story: How to calculate the intrinsic value of a stock

Analyst Recommendations for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.